John Libbey Eurotext

Innovations & Thérapeutiques en Oncologie

Immune checkpoint blockade therapy in onco-haematology Volume 3, issue 2, March-April 2017

Figures

  • Figure 1

Tables

Authors
1 Université Grenoble Alpes
CNRS, Grenoble INP, CHU Grenoble Alpes, TIMC-IMAG 38000 Grenoble
France
2 CHU de Grenoble, Institut de biologie et pathologie
UM biochimie des enzymes et des protéines
Département de biochimie toxicologie pharmacologie
BP 217
38043 Grenoble France
3 CHU de Grenoble
Service d’hématologie clinique
BP 217
38043 Grenoble France
* Tirés à part
  • Key words: immunotherapy, immunomodulators, IDO, CTLA-4, PD1
  • DOI : 10.1684/ito.2017.0078
  • Page(s) : 73-8
  • Published in: 2017

Immunotherapy with a view to restoring or stimulating patient immunity has significantly developed as an innovative onco-haematological treatment. There are currently at least two treatment approaches which make it possible to eliminate inhibition of the antitumour immune response: immune checkpoint blocking antibodies and chemical inhibitors of immunosuppressive metabolism. These strategies were initially considered individually and have more recently been used in combination with other approaches for immunotherapy and chemotherapy.